Polyclonal Antibodies Market Size - By Product (Primary Antibodies, Secondary Antibodies), Application, Route of Administration (IV, SC), Source (Rabbit, Goat, Mouse, Human), End-user, Global Forecast (2023-2032)

Description

List of Tables

Global Polyclonal Antibodies Market size will grow at a 5.9% CAGR from 2023 to 2032 due to expanding application scope in diagnostics, therapeutics, and experimental research. As life sciences and biotechnology research intensifies, there is a heightened demand for versatile antibodies. In diagnostics, polyclonal antibodies play a pivotal role in accurate detection, while their therapeutic applications address various medical conditions. With ongoing advancements and increased research activities in these domains, the polyclonal antibodies industry will expand, meeting the diverse needs of diagnostic and therapeutic applications within the healthcare and biotechnology sectors.

Organizations are actively engaged in developing polyclonal antibodies for research in the life sciences and biotechnology sectors. This contributes significantly to bolstering the polyclonal antibodies market by meeting diverse research needs and advancing scientific applications. For instance, in 2022, Amerigo Scientific, a distributor specializing in essential products and services for the biomedical and life sciences, unveiled a new polyclonal antibody targeting human blood coagulation factor XIII. Designed exclusively for research purposes, this antibody aids life science researchers in detecting blood coagulation factor XIII. It is expressly not intended for human, therapeutic, or diagnostic applications.

The polyclonal antibodies industry is segmented based on application, end-user, and region.

The contract research organizations (CROs) segment will secure a significant share by 2032, driven by CROs' pivotal role in outsourced research services, offering expertise in antibody development. With a rising demand for tailored solutions in biopharmaceutical development, CROs serve as essential partners, providing specialized services. Their proficiency in generating high-quality polyclonal antibodies will position the segment as a key driver, addressing the specific needs of the pharmaceutical and biotechnology industries and playing a crucial role in advancing scientific research.

The research application segment will capture a substantial share through 2032, attributed to the integral role these antibodies play in diverse research applications, particularly in life sciences and biotechnology. Their widespread use in experiments, diagnostics, and therapeutic research underscores their significance. With an increasing emphasis on advancing scientific understanding, the research application segment will be a cornerstone in shaping the polyclonal antibodies market, meeting the evolving needs of the research community across various disciplines.

Europe polyclonal antibodies market will register a notable CAGR from 2023 to 2032, propelled by the region's robust biopharmaceutical industry and substantial investments in research and development. The European market benefits from a mature healthcare infrastructure and a rich scientific landscape, fostering advancements in polyclonal antibody applications. The prevalence of chronic diseases and increasing demand for targeted therapeutics contribute to the region's prominence, positioning Europe as a significant force in shaping the polyclonal antibodies industry outlook.

Product Code: 7456

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast Calculation
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Polyclonal antibodies industry 360 degree synopsis, 2018 - 2032 (USD Million)
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Product trends
- 2.1.4 Application trends
- 2.1.5 Route of administration trends
- 2.1.6 Source trends
- 2.1.7 End-user trends

Chapter 3 Polyclonal Antibodies Market Insights

3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic and infectious diseases
  - 3.2.1.2 Growing demand for personalized medicines
  - 3.2.1.3 Increasing biopharmaceutical R&D activities
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringency of regulatory procedures
3.3 Growth potential analysis
- 3.3.1 By product
- 3.3.2 By application
- 3.3.3 By route of administration
- 3.3.4 By source
- 3.3.5 By end-users
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Pipeline Analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022

Chapter 5 Polyclonal Antibodies Market Estimates and Forecast, By Product, 2018-2032 (USD Million)

5.1 Key trends, by product
5.2 Primary antibodies
5.3 Secondary antibodies

Chapter 6 Polyclonal Antibodies Market Estimates and Forecast, By Application, 2018-2032 (USD Million)

6.1 Key trends, by application
6.2 Diagnostics
6.3 Therapeutics
6.4 Research

Chapter 7 Polyclonal Antibodies Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Million)

7.1 Key trends, by route of administration
7.2 Intravenous (IV)
7.3 Subcutaneous (SC)
7.4 Other routes of administration

Chapter 8 Polyclonal Antibodies Market Estimates and Forecast, By Source, 2018-2032 (USD Million)

8.1 Key trends, by source
8.2 Rabbit
8.3 Goat
8.4 Mouse
8.5 Human
8.6 Other sources

Chapter 9 Polyclonal Antibodies Market Estimates and Forecast, By End-users, 2018-2032 (USD Million)

9.1 Key trends, by end-user
9.2 Pharmaceutical and Biotechnology Companies
9.3 Academic and Research Institutes
9.4 Contract Research Organizations (CROs)
9.5 Diagnostic Laboratories
9.6 Other end-users

Chapter 10 Polyclonal Antibodies Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

10.1 Key trends, by region
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East & Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East & Africa

Chapter 11 Company Profiles

11.1 Thermo Fisher Scientific Inc.
11.2 F. Hoffmann-La Roche Ltd.
11.3 Merck Group (Merck KGaA)
11.4 Abcam plc
11.5 Bio-Rad Laboratories, Inc.
11.6 GenScript Biotech Corporation
11.7 Cell Signaling Technology, Inc.
11.8 Rockland Immunochemicals Inc.
11.9 BioLegend, Inc.
11.10 Santa Cruz Biotechnology, Inc.
11.11 Antibodies Inc.
11.12 Emergent